{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:09:43Z","timestamp":1783908583953,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Research Foundation of Anhui Institute of Translational Medicine"},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the College Excellent Youth Talent Support Program in Anhui Province"},{"name":"the Key Projects of Natural Science Research in Colleges and Universities in Anhui Province"},{"name":"Key Scientific Research Project of Anhui Provincial Department of Education"},{"name":"Mainland Visiting & Research Fellowship Program for Young Key Teachers"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PDGFRA genetic alterations are a well-established oncogenic driver in gliomas. However, targeted monotherapy against PDGFRA such as avapritinib has achieved limited clinical efficacy, and the mechanism underlying avapritinib resistance remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multi-omics analysis of clinical samples identified super-enhancer (SE) complex components. Comprehensive preclinical evaluation was performed using glioma cell lines, glioma stem cells, patient-derived cells, xenografts, and organoids. Mechanistic investigations integrated Cleavage Under Targets and Tagmentation, chromatin immunoprecipitation, co-immunoprecipitation, mass spectrometry, protein fragment complementation, and dual-luciferase reporter assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Functional and clinical analyses identified the SE complex component MED8 as significantly upregulated in gliomas and correlated with poor prognosis. MED8 was essential for tumor proliferation and survival both in vitro and in vivo. Mechanistically, MED8 cooperated with CDK7 to bind and activate the SEs of PDGFRA, sustaining high transcriptional output of this oncogene. We repurposed FDA-approved venetoclax as a first-in-class MED8-targeting agent that potently sensitizes to avapritinib, exerting synergistic effects in multiple preclinical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study delineates a novel MED8-SE-PDGFRA epigenetic axis driving resistance. The combination of avapritinib and venetoclax, co-targeting the oncogenic signal and its transcriptional regulator, presents a translatable dual-targeting strategy to improve outcomes in PDGFRA-driven glioma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03736-0","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:04:01Z","timestamp":1779177841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disrupting MED8-dependent epigenetic reprogramming augments avapritinib sensitivity in PDGFRA-driven glioma"],"prefix":"10.1186","volume":"45","author":[{"given":"Han","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erbao","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"3736_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-021-00855-2","volume":"7","author":"QJ Gai","year":"2022","unstructured":"Gai QJ, Fu Z, He J, Mao M, Yao XX, Qin Y, et al. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma. Signal Transduct Target Ther. 2022;7(1):33.","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"3736_CR2","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/neuonc\/noad065","volume":"25","author":"A Goenka","year":"2023","unstructured":"Goenka A, Song X, Tiek D, Iglesia RP, Lu M, Zeng C, et al. Oncogenic long noncoding RNA LINC02283 enhances PDGF receptor A-mediated signaling and drives glioblastoma tumorigenesis. Neuro Oncol. 2023;25(9):1592\u2013604.","journal-title":"Neuro Oncol"},{"issue":"8","key":"3736_CR3","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/neuonc\/noaf086","volume":"27","author":"X Yu","year":"2025","unstructured":"Yu X, Song X, Tiek D, Wu R, Walker M, Horbinski C, et al. Targeting PDGFRA-SHP2 signaling enhances radiotherapy in IDH1-mutant glioma. Neuro Oncol. 2025;27(8):2023\u201334.","journal-title":"Neuro Oncol"},{"issue":"4","key":"3736_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccell.2025.02.018","volume":"43","author":"L Mayr","year":"2025","unstructured":"Mayr L, Neyazi S, Schwark K, Trissal M, Beck A, Labelle J, et al. Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell. 2025;43(4):740\u2013e568.","journal-title":"Cancer Cell"},{"issue":"1","key":"3736_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13046-023-02763-5","volume":"42","author":"M Wang","year":"2023","unstructured":"Wang M, Chen Q, Wang S, Xie H, Liu J, Huang R, et al. Super-enhancers complexes zoom in transcription in cancer. J Exp Clin Cancer Res. 2023;42(1):183.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"3736_CR6","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/neuonc\/noae065","volume":"26","author":"H Xie","year":"2024","unstructured":"Xie H, Jiang Y, Xiang Y, Wu B, Zhao J, Huang R, et al. Super-enhancer-driven LIF promotes the mesenchymal transition in glioblastoma by activating ITGB2 signaling feedback in microglia. Neuro Oncol. 2024;26(8):1438\u201352.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3736_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-020-00145-w","volume":"2","author":"M Gartlgruber","year":"2021","unstructured":"Gartlgruber M, Sharma AK, Quintero A, Dreidax D, Jansky S, Park YG, et al. Super enhancers define regulatory subtypes and cell identity in neuroblastoma. Nat Cancer. 2021;2(1):114\u201328.","journal-title":"Nat Cancer"},{"issue":"1","key":"3736_CR8","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41467-025-56645-9","volume":"16","author":"YF Cao","year":"2025","unstructured":"Cao YF, Wang H, Sun Y, Tong BB, Shi WQ, Peng L, et al. Nuclear ANLN regulates transcription initiation related Pol II clustering and target gene expression. Nat Commun. 2025;16(1):1271.","journal-title":"Nat Commun"},{"issue":"1","key":"3736_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/neuonc\/noad143","volume":"26","author":"I Bhutada","year":"2024","unstructured":"Bhutada I, Khambati F, Cheng SY, Tiek DM, Duckett D, Lawrence H, et al. CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity. Neuro Oncol. 2024;26(1):70\u201384.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3736_CR10","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-021-24137-1","volume":"12","author":"J Dong","year":"2021","unstructured":"Dong J, Li J, Li Y, Ma Z, Yu Y, Wang CY. Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma. Nat Commun. 2021;12(1):3974.","journal-title":"Nat Commun"},{"key":"3736_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2021.03.012","volume":"507","author":"PM Chow","year":"2021","unstructured":"Chow PM, Chang YW, Kuo KL, Lin WC, Liu SH, Huang KH. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemona\u00efve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway. Cancer Lett. 2021;507:70\u20139.","journal-title":"Cancer Lett"},{"issue":"2","key":"3736_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320\u201334.","journal-title":"Cell"},{"key":"3736_CR13","doi-asserted-by":"publisher","first-page":"122483","DOI":"10.1016\/j.biomaterials.2024.122483","volume":"306","author":"YD Xu","year":"2024","unstructured":"Xu YD, Liang XC, Li ZP, Wu ZS, Yang J, Jia SZ, et al. Apoptotic body-inspired nanotherapeutics efficiently attenuate osteoarthritis by targeting BRD4-regulated synovial macrophage polarization. Biomaterials. 2024;306:122483.","journal-title":"Biomaterials"},{"key":"3736_CR14","doi-asserted-by":"crossref","unstructured":"Xie H, Ji T, Zhang C, Cheng M, Wang R, Wu Y, et al. Co-activation of super-enhancer complex SOX2 and HDAC1 confers temozolomide resistance by promoting PDGFB transcription in glioblastoma. Neuro Oncol. 2026;28(1):55\u201369.","DOI":"10.1093\/neuonc\/noaf219"},{"issue":"7940","key":"3736_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41586-022-05504-4","volume":"612","author":"Z Xu","year":"2022","unstructured":"Xu Z, Lee DS, Chandran S, Le VT, Bump R, Yasis J, et al. Structural variants drive context-dependent oncogene activation in cancer. Nature. 2022;612(7940):564\u201372.","journal-title":"Nature"},{"issue":"26","key":"3736_CR16","doi-asserted-by":"publisher","first-page":"5826","DOI":"10.1016\/j.cell.2023.11.030","volume":"186","author":"JW Blayney","year":"2023","unstructured":"Blayney JW, Francis H, Rampasekova A, Camellato B, Mitchell L, Stolper R, et al. Super-enhancers include classical enhancers and facilitators to fully activate gene expression. Cell. 2023;186(26):5826\u2013e3918.","journal-title":"Cell"},{"issue":"4","key":"3736_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/pharmrev.120.000170","volume":"73","author":"S Mathien","year":"2021","unstructured":"Mathien S, Tesni\u00e8re C, Meloche S. Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential. Pharmacol Rev. 2021;73(4):263\u201396.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"3736_CR18","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1038\/s41467-021-24843-w","volume":"12","author":"M Liu","year":"2021","unstructured":"Liu M, Cao S, He L, Gao J, Arab JP, Cui H, et al. Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis. Nat Commun. 2021;12(1):4560.","journal-title":"Nat Commun"},{"issue":"21","key":"3736_CR19","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1158\/0008-5472.CAN-23-3995","volume":"84","author":"MW Lewis","year":"2024","unstructured":"Lewis MW, King CM, Wisniewska K, Regner MJ, Coffey A, Kelly MR, et al. CRISPR Screening of Transcribed Super-Enhancers Identifies Drivers of Triple-Negative Breast Cancer Progression. Cancer Res. 2024;84(21):3684\u2013700.","journal-title":"Cancer Res"},{"issue":"12","key":"3736_CR20","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/j.molcel.2024.05.007","volume":"84","author":"T Velychko","year":"2024","unstructured":"Velychko T, Mohammad E, Ferrer-Vicens I, Parfentev I, Werner M, Studniarek C, et al. CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release. Mol Cell. 2024;84(12):2287\u2013e30310.","journal-title":"Mol Cell"},{"issue":"5","key":"3736_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stem.2024.03.008","volume":"31","author":"S Yin","year":"2024","unstructured":"Yin S, Yu Y, Wu N, Zhuo M, Wang Y, Niu Y, et al. Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. Cell Stem Cell. 2024;31(5):717\u2013e338.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"3736_CR22","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1038\/s41467-019-12846-7","volume":"10","author":"D Su","year":"2019","unstructured":"Su D, Zhang D, Jin J, Ying L, Han M, Chen K, et al. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nat Commun. 2019;10(1):5076.","journal-title":"Nat Commun"},{"issue":"1","key":"3736_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41392-022-00958-4","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Correction: Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7(1):110.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"3736_CR24","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-21-4002","volume":"28","author":"K Madhavan","year":"2022","unstructured":"Madhavan K, Balakrishnan I, Lakshmanachetty S, Pierce A, Sanford B, Fosmire S, et al. Venetoclax Cooperates with Ionizing Radiation to Attenuate Diffuse Midline Glioma Tumor Growth. Clin Cancer Res. 2022;28(11):2409\u201324.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"3736_CR25","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1182\/blood.2024024341","volume":"144","author":"MX Luo","year":"2024","unstructured":"Luo MX, Tan T, Trussart M, Poch A, Nguyen TMH, Speed TP, et al. Venetoclax dose escalation rapidly activates a BAFF\/BCL-2 survival axis in chronic lymphocytic leukemia. Blood. 2024;144(26):2748\u201361.","journal-title":"Blood"},{"issue":"4","key":"3736_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s43018-022-00359-0","volume":"3","author":"B Herpers","year":"2022","unstructured":"Herpers B, Eppink B, James MI, Cortina C, Ca\u00f1ellas-Socias A, Boj SF, et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors. Nat Cancer. 2022;3(4):418\u201336.","journal-title":"Nat Cancer"},{"issue":"8","key":"3736_CR27","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41556-019-0360-z","volume":"21","author":"M Boretto","year":"2019","unstructured":"Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B, et al. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 2019;21(8):1041\u201351.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"3736_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41467-024-55487-1","volume":"16","author":"S Bastola","year":"2025","unstructured":"Bastola S, Pavlyukov MS, Sharma N, Ghochani Y, Nakano MA, Muthukrishnan SD, et al. Endothelial-secreted Endocan activates PDGFRA and regulates vascularity and spatial phenotype in glioblastoma. Nat Commun. 2025;16(1):471.","journal-title":"Nat Commun"},{"issue":"10","key":"3736_CR29","doi-asserted-by":"publisher","first-page":"109656","DOI":"10.1016\/j.celrep.2021.109656","volume":"36","author":"G Goranci-Buzhala","year":"2021","unstructured":"Goranci-Buzhala G, Mariappan A, Ricci-Vitiani L, Josipovic N, Pacioni S, Gottardo M, et al. Cilium induction triggers differentiation of glioma stem cells. Cell Rep. 2021;36(10):109656.","journal-title":"Cell Rep"},{"issue":"1","key":"3736_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.molcel.2021.11.015","volume":"82","author":"D Sooraj","year":"2022","unstructured":"Sooraj D, Sun C, Doan A, Garama DJ, Dannappel MV, Zhu D, et al. MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase. Mol Cell. 2022;82(1):123\u2013e397.","journal-title":"Mol Cell"},{"issue":"1","key":"3736_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-020-01301-7","volume":"20","author":"Y Wei","year":"2021","unstructured":"Wei Y, Li C, Bian H, Qian W, Jin K, Xu T, et al. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Mol Cancer. 2021;20(1):5.","journal-title":"Mol Cancer"},{"issue":"7572","key":"3736_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature14904","volume":"526","author":"HE Pelish","year":"2015","unstructured":"Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature. 2015;526(7572):273\u20136.","journal-title":"Nature"},{"issue":"11","key":"3736_CR33","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1158\/1078-0432.CCR-19-1418","volume":"26","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu W, Zou C, Zhao Z, Lai Y, Shi Z, et al. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor. Clin Cancer Res. 2020;26(11):2681\u201392.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3736_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41419-023-05892-z","volume":"14","author":"Z Chen","year":"2023","unstructured":"Chen Z, Tian D, Chen X, Cheng M, Xie H, Zhao J, et al. Super-enhancer-driven lncRNA LIMD1-AS1 activated by CDK7 promotes glioma progression. Cell Death Dis. 2023;14(6):383.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3736_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/10409238.2013.840259","volume":"48","author":"ZC Poss","year":"2013","unstructured":"Poss ZC, Ebmeier CC, Taatjes DJ. The Mediator complex and transcription regulation. Crit Rev Biochem Mol Biol. 2013;48(6):575\u2013608.","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"2","key":"3736_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.fertnstert.2016.10.035","volume":"107","author":"SA Yatsenko","year":"2017","unstructured":"Yatsenko SA, Mittal P, Wood-Trageser MA, Jones MW, Surti U, Edwards RP, et al. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. Fertil Steril. 2017;107(2):457\u2013. \u2013\u200966.e9.","journal-title":"Fertil Steril"},{"issue":"1","key":"3736_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-020-00926-x","volume":"13","author":"J Wang","year":"2020","unstructured":"Wang J, Zhang R, Lin Z, Zhang S, Chen Y, Tang J, et al. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38\u03b1\/MYC\/PD-L1 signaling in non-small cell lung cancer. J Hematol Oncol. 2020;13(1):99.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3736_CR38","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1158\/2159-8290.CD-19-0189","volume":"9","author":"RU Rasool","year":"2019","unstructured":"Rasool RU, Natesan R, Deng Q, Aras S, Lal P, Sander Effron S, et al. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discov. 2019;9(11):1538\u201355.","journal-title":"Cancer Discov"},{"issue":"4","key":"3736_CR39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019;178(4):835\u2013e4921.","journal-title":"Cell"},{"issue":"3","key":"3736_CR40","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11912-025-01636-8","volume":"27","author":"G Strauss","year":"2025","unstructured":"Strauss G, George S. Gastrointestinal Stromal Tumors. Curr Oncol Rep. 2025;27(3):312\u201321.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"3736_CR41","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1172\/JCI133310","volume":"130","author":"Z Miklja","year":"2020","unstructured":"Miklja Z, Yadav VN, Cartaxo RT, Siada R, Thomas CC, Cummings JR, et al. Everolimus improves the efficacy of dasatinib in PDGFR\u03b1-driven glioma. J Clin Invest. 2020;130(10):5313\u201325.","journal-title":"J Clin Invest"},{"issue":"1","key":"3736_CR42","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1038\/s41467-018-06949-w","volume":"9","author":"CKM Ip","year":"2018","unstructured":"Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, Leonard PG, et al. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nat Commun. 2018;9(1):4583.","journal-title":"Nat Commun"},{"issue":"3","key":"3736_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov. 2023;22(3):213\u201334.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3736_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","volume":"8","author":"S Guo","year":"2023","unstructured":"Guo S, Yao Y, Tang Y, Xin Z, Wu D, Ni C, et al. Radiation-induced tumor immune microenvironments and potential targets for combination therapy. Signal Transduct Target Ther. 2023;8(1):205.","journal-title":"Signal Transduct Target Ther"},{"issue":"20","key":"3736_CR45","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","volume":"140","author":"D Thomalla","year":"2022","unstructured":"Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling CD, et al. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022;140(20):2113\u201326.","journal-title":"Blood"},{"issue":"12","key":"3736_CR46","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630\u201342.","journal-title":"Lancet Oncol"},{"key":"3736_CR47","doi-asserted-by":"crossref","unstructured":"Zhao K, Braun M, Meyer L, Otte K, Raifer H, Helmprobst F, et al. A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1. Cells. 2024;13(7):632.","DOI":"10.3390\/cells13070632"},{"issue":"7","key":"3736_CR48","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41418-022-00977-2","volume":"29","author":"D Moujalled","year":"2022","unstructured":"Moujalled D, Southon AG, Saleh E, Brinkmann K, Ke F, Iliopoulos M, et al. BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells. Cell Death Differ. 2022;29(7):1335\u201348.","journal-title":"Cell Death Differ"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03736-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03736-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:01:37Z","timestamp":1783908097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03736-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3736"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03736-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of The Second Affiliated Hospital of Anhui Medical University, and written informed consent was obtained from all patients. All animal experiments were conducted with the approval of the Animal Research Committee of Anhui Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The content of this manuscript has not been previously published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}